JLS Fund

Immunis a private biotechnology company developing a novel treatment for age and disease-related immune decline.

Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York that specializes in developing novel psychotropic drugs aimed at treating mental illnesses. Established in 2019, the company focuses on creating innovative compounds that enhance the therapeutic benefits of classic psychedelics while improving safety, tolerability, duration, and efficacy. Gilgamesh addresses the growing global mental health crisis by providing treatments for various neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. Through a combination of medicinal chemistry and drug development expertise, the company aims to accelerate the availability of effective therapies, ultimately improving the quality of life for individuals suffering from central nervous system disorders.

Homecoming is a provider of patient engagement tools for psychedelic therapy.

Fluence offers continuing education and certificate programs in psychedelic integration and psychedelic-assisted therapy. Our programs are designed for licensed professionals and advanced graduate students who have an opportunity to work with patient populations. Although none of our courses have specific prerequisites, a basic working knowledge of the mental health field and practice of psychotherapy is helpful. Our programs are interactive; we engage in discussion, demonstration, self-reflection exercises, and role plays. Some of our classes and programs are reserved for licensed clinicians, but many are open to anyone who wishes to attend.

Psilera is a biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases and mental health disorders. The company focuses on creating a new class of neurological medicines, with its lead asset, PSIL-006, being a non-hallucinogenic psilocybin derivative aimed at treating frontotemporal dementia (FTD). Psilera's approach involves repurposing psychoactive natural products to develop next-generation therapies that enhance cognitive function and address mood and substance use disorders. Committed to scientific excellence, Psilera aims to transform the lives of individuals affected by these challenging conditions through its pioneering research and development efforts.

Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York that specializes in developing novel psychotropic drugs aimed at treating mental illnesses. Established in 2019, the company focuses on creating innovative compounds that enhance the therapeutic benefits of classic psychedelics while improving safety, tolerability, duration, and efficacy. Gilgamesh addresses the growing global mental health crisis by providing treatments for various neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. Through a combination of medicinal chemistry and drug development expertise, the company aims to accelerate the availability of effective therapies, ultimately improving the quality of life for individuals suffering from central nervous system disorders.

WeSana Health is a life sciences company focused on the advancement of psilocybin-based medicine. Founded in 2020 by Daniel Carcillo, the company is headquartered in Homer Glen, Illinois. WeSana Health is actively exploring new business opportunities to further its mission in the burgeoning field of psychedelics, aiming to develop innovative therapeutic solutions for various mental health conditions.